This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-30. Anything still debated is marked as such rather than presented as settled.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by RP-HPLC | Area percentage of the main peak |
| Identity confirmation | Electrospray ionization mass spectrometry | Observed mass compared with the theoretical value near 751.9 Da |
| Recommended dry storage | -20 °C, desiccated | -80 °C for multi-year archival material |
| Solution handling | Prepare fresh; avoid long storage | Sterile filtration reduces microbial load |
| Common synonyms | TKPRPGP; TP-7 | Sequence code and laboratory designation used interchangeably |
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
The lanthanides and late actinides usually have high fourth ionisation energies and hence rarely surpass the +3 oxidation state, whereas early actinides have low fourth ionisation energies and so for example neptunium and plutonium can reach +7. The very last actinides go further than the lanthanides towards low oxidation states: mendelevium is more easily reduced to the +2 state than thulium or even europium (the lanthanide with the most stable +2 state, on account of its half-filled f-shell), and nobelium outright favours +2 over +3, in contrast to ytterbium. As elements in the same group share the same valence configurations, they usually exhibit similar chemical behaviour. For example, the alkali metals in the first group all have one valence electron, and form a very homogeneous class of elements: they are all soft and reactive metals. However, there are many factors involved, and groups can often be rather heterogeneous. For instance, hydrogen also has one valence electron and is in the same group as the alkali metals, but its chemical behaviour is quite different. The stable elements of group 14 comprise a nonmetal (carbon), two semiconductors (silicon and germanium), and two metals (tin and lead); they are nonetheless united by having four valence electrons. This often leads to similarities in maximum and minimum oxidation states (e.g. sulfur and selenium in group 16 both have maximum oxidation state +6, as in SO3 and SeO3, and minimum oxidation state −2, as in sulfides and selenides); but not always (e.g.
Tc is maximal near 92 K (−181.2 °C) when x ≈ 0.15 and the structure is orthorhombic. Superconductivity disappears at x ≈ 0.6, where the structural transformation of YBCO occurs from orthorhombic to tetragonal.
=== Negative === When insulin binds to the cell's receptor, it results in negative feedback by limiting or stopping some other actions in the cell. It inhibits the release and production of glucose from the cells which is an important part in reducing the glucose blood level. Insulin will also inhibit the breakdown of glycogen into glucose by inhibiting the expression of the enzymes that catalyzes the degradation of glycogen. An example of negative feedback is slowing or stopping the intake of glucose after the pathway was activated. Negative feedback is shown in the insulin signal transduction pathway by constricting the phosphorylation of the insulin-stimulated tyrosine. The enzyme that deactivates or phosphorylates the insulin-stimulated tyrosine is called tyrosine phosphatases (PTPases). When activated, this enzyme provides a negative feedback by catalyzing the dephosphorylation of the insulin receptors. The dephosphorylation of the insulin receptor slows down glucose intake by inhibiting the activation (phosphorylation) of proteins responsible for further steps of the insulin transduction pathway.
== History == George W. Corner and Willard M. Allen discovered the hormonal action of progesterone in 1929. By 1931–1932, nearly pure crystalline material of high progestational activity had been isolated from the corpus luteum of animals; by 1934, pure crystalline progesterone had been refined and obtained, and the chemical structure of progesterone was determined. This was achieved by Adolf Butenandt at the Chemisches Institut of Gdańsk Technical University in Danzig, who extracted this new compound from several thousand liters of urine. Chemical synthesis of progesterone from stigmasterol and pregnanediol was accomplished later that year. Up to this point, progesterone, known generically as corpus luteum hormone, had been being referred to by several groups by different names, including corporin, lutein, luteosterone, and progestin. In 1935, at the time of the Second International Conference on the Standardization of Sex Hormones in London, England, a compromise was reached between the groups, and the name 'progesterone' (progestational steroidal ketone) was created.
Sources: en.wikipedia.org
=== Mass spectrometry === Mass spectrometry provides information about the structure and composition of the complexes. Spectra for metal polycarbonyls are often easily interpretable, because the dominant fragmentation process is the loss of carbonyl ligands (m/z = 28).
Clascoterone, sold under the brand name Winlevi, is an antiandrogen medication which is used topically in the treatment of acne. The medication is used as a cream by application to the skin, for instance the face and scalp. Clascoterone is an antiandrogen, or antagonist of the androgen receptor (AR), the biological target of androgens such as testosterone and dihydrotestosterone. It shows minimal systemic absorption when applied to skin. Clascoterone was developed by Cassiopea and was approved for medical use in the United States in August 2020 and in the European Union in October 2025. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
2000 – 2008 Member of the board of the Technical University of Denmark. 2000 – 2003 Member of the Academy of Technical Sciences, Denmark 2003 – 2004 President of the Academy of Technical Sciences, Denmark 2006 – 2012 Member of the board of Cellartis AB, Sweden 2012 – 2019 Member of the board of the University of Copenhagen (chairman from 2017 to 2020) 2014 - 2016 Chairman of the board, Steno Diabetes Center, Denmark 2018 - 2019 Board member, Symphogen A/S, Denmark 2020 - Member of the board of BB Biotech AG, Switzerland
Sources: en.wikipedia.org
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.
A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.
A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.